ArticleJournal of veterinary science2025
Identification of MAPK3 inhibitors against
Article in Journal of veterinary science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
importanceLeishmaniasis, caused by
objectiveThis study evaluated the potential MAPK3 inhibitors capable of targeting
methodsFive compounds from the NCI database were screened using an ADP-Glo Kinase Assay for MAPK3 inhibition. Half-maximal inhibitory concentration (IC₅₀) analysis was performed to determine their potency. Molecular docking and molecular dynamics simulations were conducted to assess the binding interactions and stability. Cell-based assays were performed to evaluate the efficacy of these compounds against
resultsNSC107522, NSC196515, and NSC84100 inhibited MAPK3, with IC₅₀ values of 2.69 µM, 4.96 µM, and 10.59 µM, respectively. NSC107522 showed the strongest binding affinity (ΔG CONCLUSIONS AND RELEVANCE: NSC107522 and NSC84100 are promising MAPK3 inhibitors with species-specific activity. NSC107522 targets
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.